Journal of Radiotherapy in Practice



Original Article

p53 expression, Ki-67 status, and cell density have no prognostic significance in glioblastomas treated with radio-chemotherapy


M.W. Gross a1c1, K. Nashwan a1, H.-D. Mennel a2 and R. Engenhart-Cabillic a1
a1 Department of Radiotherapy and Radio-Oncology, University of Giessen and Marburg, Marburg, Germany
a2 Department of Neuropathology, University of Giessen and Marburg, Marburg, Germany

Article author query
gross mw   [PubMed][Google Scholar] 
nashwan k   [PubMed][Google Scholar] 
mennel h-d   [PubMed][Google Scholar] 
engenhart-cabillic r   [PubMed][Google Scholar] 

Abstract

Purpose: To identify subgroups in glioblastoma multiforme (GBM) with different susceptibilities to radio-chemotherapy by p53 protein and Ki-67 expression.

Patients and Methods: Thirty-one patients with primary GBM underwent a combined radio-chemotherapy with topotecan. Percentage of cells expressing p53 protein and Ki-67 antigen was determined immunohistochemically. Additionally, the cell density within the tumour tissue was measured.

Results: Median percentages of p53 and Ki-67 expressing cells were 4.3% (range = 0–28%) and 12.0% (range = 0–28%), respectively. Dividing the cases into two groups by high or low p53 protein 1-year disease-free survival rates were 13.3% and 23.6%. High or low Ki-67 expression showed one-year disease-free survival rates of 18.8% and 17.1%. Neither p53 nor Ki-67 expression showed a significant correlation with disease-free survival or overall survival. Median cell density was 252 cells/field (range = 42–595). 1-year disease-free survival rates were 14.5% and 21.7% in high and low cell density group, respectively. A significant correlation with progression-free survival was observed, whereas the stratification into two groups revealed no significance. Cell density showed a significant inverse correlation with p53 and Ki-67 immunopositivity.

Conclusion: p53 protein and Ki-67 expression seem to be inappropriate for the estimation of prognosis in patients receiving a combined radio-chemotherapy with topotecan.

(Published Online September 27 2006)


Key Words: p53; Ki-67; radio-chemotherapy; prognostic factor.

Correspondence:
c1 Correspondence to: Markus W. Gross MD, Department of Radiotherapy and Radio-Oncology, University of Giessen and Marburg, Baldingerstr. D-35033 Marburg, Germany. E-mail: gross@med.uni-marburg.de


0Comments